WHO Efforts to Enhance Access to Vaccine Supply

UNICEF Vaccine Industry Consultation – Copenhagen, October 2017

Tania Cernuschi, Vaccine Supply | Supply, Technologies, and Financing
Expanded Programme on Immunization (EPI) | Department of Immunization, Vaccines and Biologicals (IVB)
<table>
<thead>
<tr>
<th></th>
<th>SUSTAINABLE FINANCING AND SUPPLY FOR IMMUNIZATION – WHO’s work</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Improving country regulatory environment</td>
</tr>
<tr>
<td></td>
<td>NRAs strengthening, streamlining of registration requirements, PQ programme</td>
</tr>
<tr>
<td>2</td>
<td>Guiding vaccine research and development</td>
</tr>
<tr>
<td></td>
<td>R&amp;D Blueprint – priority pathogens &amp; TPPs, position papers</td>
</tr>
<tr>
<td>3</td>
<td>Financing for vaccines and immunization</td>
</tr>
<tr>
<td></td>
<td>CMYPs, immunization financing assessments, monitoring of financial flows &amp; advocacy</td>
</tr>
<tr>
<td>4</td>
<td>Strengthening national supply chain systems</td>
</tr>
<tr>
<td></td>
<td>EVMs, stock-out monitoring, Gavi supply chain strategy</td>
</tr>
<tr>
<td>5</td>
<td>Scaling up innovative products and thermostability</td>
</tr>
<tr>
<td></td>
<td>CTC, new delivery technologies &amp; packaging, TSE</td>
</tr>
<tr>
<td>6</td>
<td>Stockpiling of vaccines for outbreak response</td>
</tr>
<tr>
<td></td>
<td>YF, cholera, meningitis, influenza, polio, smallpox</td>
</tr>
<tr>
<td>7</td>
<td>Information for access</td>
</tr>
<tr>
<td></td>
<td>Market intelligence for policy making &amp; country support</td>
</tr>
</tbody>
</table>
WHO’s work in context

Why are we engaging?
Global vaccine demand & partner support mapped

Gavi partners shape market for and fund specific vaccines in poorer countries (~70)

UNICEF procures for Gavi-eligible countries and some non-Gavi Middle Income Countries (~100)

The PAHO RF supports financing and procurement in the American Region (~40 countries)

Self-procuring countries lack market information & support and face challenges to access

Source: Global Vaccine Market Model (GVMM) Demand Module, Linksbridge, SPC, Bill & Melinda Gates Foundation funded project, July 2017
Access to vaccines in MICs

Non Gavi MICs represent almost 40% PCV3 unimmunised and 50% of countries with declining DTP3 coverage

Source: WHO GVAP Report 2017 – WJENIC/JRF data
Member States have asked WHO to take action

Resolution 54.11 – WHA – May 2001

Obj. 5 Global Vaccine Action Plan – GVAP

SAGE Recommendation – MIC Strategy

Resolution 68.6 – WHA – May 2015

Resolution 69.25 – WHA – May 2016

SAGE Recommendation April 2015
Information for Access in a nutshell

1. Collecting, analyzing and distributing price/procurement/demand/supply data
2. Conducting in depth global market analysis for vaccines at risk
3. Guiding supply and demand dynamics to address vaccine shortages
4. Technical assistance to countries to access supply
5. Designing strategies to enhance affordability
6. Guidelines/tools for country forecasting & procurement
Global Vaccine Market Intelligence Hub (V3P+)

What information do we have and how can it be used?
The Vaccine Price, Product, Procurement Initiative (V3P)

- Through the WHO-UNICEF JRF, 144 countries are participating (87% of non-Gavi MICs; 84% of world)
- Countries share info on vaccines, products, suppliers, prices, volumes, procurement & payment method, contract duration, incoterms
- Over the next 3 years, we will further invest in V3P leveraging other sources of information – GVMM, BMGF Funded Project = V3P+

Note: The graph represents all countries that have directly shared price data with V3P, regardless of the quality of the data.

AFR: region of Africa; AMR: region of the Americas; EMR: Eastern Mediterranean region; EUR: European region; SEAR: South-East Asia Region; WPR: Western Pacific Region
What is the information gap and how can we close it?

1. **NEED**
   
   Countries lack visibility into vaccine markets for decision making

2. **ENABLER**
   
   Identifying price ranges and supplier, product, procurement options

3. **BENEFIT**
   
   Informed planning & procurement leading to sustainable demand
Informed procurement – a few examples
What is the information gap and how can we close it?

**NEED**

1. Countries lack visibility into vaccine markets for decision making

2. Missing global view of vaccine market preventing risk management

**ENABLER**

- Identifying price ranges and supplier, product, procurement options
- Complement existing information on vaccine markets from Gavi, UNICEF and PAHO RF

**BENEFIT**

- Informed planning & procurement leading to sustainable demand
- Informed risk identification & target actions to manage vaccine shortages
Overview of global vaccine market

Non-Gavi MICs represent ~40% of global vaccine market by volume and ~16% by value

Source: V3P& Global Vaccine Market Model (GVMM), Linksbridge, SPC, Bill & Melinda Gates Foundation funded project, September 2017
What is the information gap and how can we close it?

**NEED**

1. Countries lack visibility into vaccine markets for decision making

2. Missing global view of vaccine market preventing risk management

3. Several countries cannot access sustainable & fair pricing

**ENABLER**

- Identifying price ranges and supplier, product, procurement options
- Complement existing information on vaccine markets from Gavi, UNICEF and PAHO RF
- Completing understanding of global pricing dynamics

**BENEFIT**

- Informed planning & procurement leading to sustainable demand
- Informed risk identification & target actions to manage vaccine shortages
- Informed dialogue on fair pricing
Informed dialogue on fair pricing

- There is a clear association between GNI per capita and price level
- We also observe larger price variation for higher income:
  - non-Gavi MICs, max price = 14x min
  - HICs, max price = 30x min
- We can improve transparency of pricing strategies and encourage fair pricing to strengthen access

Note: The boxes on the graph show the median (centre of the box), a box above and below the median for the nearest quartiles, and a set of “whiskers” that extend to the entire data range.
Policies & strategies to enhance access

Fair Pricing Forum & Humanitarian Mechanism
A global dialogue to explore strategies for establishing fair prices that is sustainable for health systems and for innovation

Participants: 250 participants from Member states, IGOs, NGOs, academia and industry

Organized jointly by WHO and the Ministry of Health, Welfare and Sport of The Netherlands

The Forum took place in Amsterdam, the Netherlands on 10-11 May 2017

For more information, please see http://www.fairpricingforum2017.nl/home
WHO, UNICEF, MSF and Save the Children have launched the Humanitarian Mechanism in May 2017.

**Aim:** to facilitate timely access to affordable supply for entities such as Civil Society Organizations, Governments or UN Agencies who are procuring on behalf of populations facing humanitarian emergencies.

The mechanism currently covers access to PCV vaccines by CSOs and UN agencies from all available manufacturers at US$ ~ 3 per dose.

Since launch, the mechanism has been used 6 times (+3 during pilot phase).

WHO, UNICEF, MSF and Save the Children encourage all vaccine manufacturers to offer additional relevant products under the mechanism.
How do we support countries?
Price, procurement, market fact sheets

We are testing different tools to share information with countries

**Country Fact Sheets**

**MARKET UPDATE BCG VACCINE**

**Key Takeaways**

- For 2017, BCG vaccine supply is estimated to be 1.5 times greater than forecasted demand. This excess supply is reassuring given the instability of the manufacturing process and is important progress from the restricted supply situation in recent years.

- However, demand flexibility is limited due to product registration constraints and supply is still concentrated, with a few large suppliers with prequalified products serving most countries. Consequently, shortages may still occur.

**QUICK STATS**

**NUMBER OF PRODUCTS**

1

**TOTAL NUMBER OF SUPPLIERS**

19

**2017 ESTIMATED MAXIMUM GLOBAL SUPPLY**

~500M doses

**2017 FORECASTED GLOBAL DEMAND**

~350M doses

**2015 REPORTED PRICE RANGE**

US $0.04-$15.08 (Median: $0.52)

---

**Prices for Gavi Transitioning Countries**

<table>
<thead>
<tr>
<th></th>
<th>Intro with Gavi 2-dose vial</th>
<th>GSK 2-dose vial</th>
<th>Pfizer 1-dose vial</th>
<th>Pfizer 4-dose vial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angola</td>
<td>✓</td>
<td>NE</td>
<td>$3.30</td>
<td>$3.10</td>
</tr>
<tr>
<td>Armenia</td>
<td>✓</td>
<td>NE</td>
<td>$3.30</td>
<td>$3.10</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>✓</td>
<td>NE</td>
<td>$3.30</td>
<td>$3.10</td>
</tr>
<tr>
<td>Bhutan</td>
<td>X</td>
<td>$3.50/3.05</td>
<td>$3.30</td>
<td>NE</td>
</tr>
<tr>
<td>Bolivia</td>
<td>✓</td>
<td>NE</td>
<td>$3.30</td>
<td>$3.10</td>
</tr>
<tr>
<td>Congo, Rep</td>
<td>✓</td>
<td>NE</td>
<td>$3.30</td>
<td>$3.10</td>
</tr>
<tr>
<td>Cuba</td>
<td>X</td>
<td>$3.50/3.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Georgia</td>
<td>✓</td>
<td>$3.50/3.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guyana</td>
<td>✓</td>
<td>NE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Honduras</td>
<td>✓</td>
<td>NE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>X</td>
<td>$3.50/3.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kiribati</td>
<td>✓</td>
<td>NE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moldova</td>
<td>✓</td>
<td>NE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mongolia</td>
<td>✓</td>
<td>NE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicaragua</td>
<td>✓</td>
<td>NE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PNG</td>
<td>✓</td>
<td>NE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>X</td>
<td>$3.50/3.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timor-Leste</td>
<td>X</td>
<td>$3.50/3.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ukraine</td>
<td>X</td>
<td>NE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uzbekistan</td>
<td>✓</td>
<td>NE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vietnam</td>
<td>X</td>
<td>$3.50/3.0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Engaging suppliers

How can we best work together?
How can we best work together?

- We regularly collect information from countries, UNICEF, PAHO RF on vaccine procurement.
- We also collect information from suppliers on ad-hoc basis. *Would manufacturers engage to share information more regularly?* E.g. products, registration.
- Would it be useful to also *regularly collect demand forecasts from self-procuring countries*?
- *What other information* would suppliers find useful to enhance access?
- *How best to share information* collected and results of analysis?
- What are the key efforts on supply and demand side that must accompany V3P?
Thank you!

Tania Cernuschi, Vaccine Supply
Supply, Technologies, and Financing
Expanded Programme on Immunization (EPI)
Dept of Immunization, Vaccines and Biologicals
cernuscht@who.int